VANLANDINGHAM JACOB PH.D 4
4 · Odyssey Health, Inc. · Filed Jun 8, 2022
Insider Transaction Report
Form 4
VANLANDINGHAM JACOB PH.D
Director
Transactions
- Award
Stock Option (Right to Buy)
2022-05-19$0.30/sh+100,000$30,000→ 1,100,000 totalExercise: $0.30Exp: 2032-05-19→ Common Stock (100,000 underlying)
Footnotes (1)
- [F1]Vesting Schedule: 50% vest on first dosed subject of Phase 2 Trial; 50% on last dosed subject of Phase 2 Trial.